How much are atypical antipsychotic agents being used, and do they reach the populations who need them? A Canadian experience (Q44179697)

30 November 2017

title

How much are atypical antipsychotic agents being used, and do they reach the populations who need them? A Canadian experience (English)

1 reference

30 November 2017

2

Gary Remington

1 reference

30 November 2017

Carolyn S Dewa

1

1 reference

30 November 2017

Nathan Herrmann

series ordinal

3

1 reference

30 November 2017

Joan Fearnley

series ordinal

4

1 reference

30 November 2017

Paula Goering

series ordinal

5

1 reference

30 November 2017

publication date

1 September 2002

1 reference

30 November 2017

published in

Clinical Therapeutics

1 reference

30 November 2017

volume

24

1 reference

30 November 2017

issue

9

1 reference

30 November 2017

page(s)

1466-1476

1 reference

Incidence and predictors of drug-induced parkinsonism in older psychiatric patients treated with very low doses of neuroleptics

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980050-9

7 January 2021

The economic burden of schizophrenia in Canada.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980050-9

7 January 2021

One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980050-9

7 January 2021

Recommendations for the management of behavioral and psychological symptoms of dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980050-9

7 January 2021

Atypical antipsychotics: are some more atypical than others?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980050-9

7 January 2021

New atypical antipsychotics. Experience and utility in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980050-9

7 January 2021

Tardive dyskinesia and atypical antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980050-9

7 January 2021

Lessons learned from trends in psychotropic drug expenditures in a canadian province

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980050-9

7 January 2021

Using forecasting models to estimate the effects of changes in the composition of claims for selective serotonin reuptake inhibitors on expenditures.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980050-9

7 January 2021

Pharmacologic treatment of schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980050-9

7 January 2021

Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980050-9

7 January 2021

Pharmacological management of schizophrenia in older patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980050-9

7 January 2021

A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980050-9

7 January 2021

Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980050-9

7 January 2021

Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980050-9

7 January 2021

Long-Term use of quetiapine in elderly patients with psychotic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980050-9

7 January 2021

Psychotropic drug use and the risk of hip fracture

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980050-9

7 January 2021

Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980050-9

7 January 2021

Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980050-9

7 January 2021

Risperidone: how good is the evidence for efficacy?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980050-9

7 January 2021

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980050-9

7 January 2021

Pharmacoeconomics of the new antipsychotics for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980050-9

7 January 2021

10.1016/S0149-2918(02)80050-9

Identifiers

DOI

1 reference

30 November 2017

1 reference